Alkaline phosphatase-based treatments of celiac disease
AssigneeTheriva Biologics, Inc.
InventorMichael KALEKO
Life of this patent
Estimating the term…
Abstract
The present disclosure relates, inter alia, to therapeutic intestinal alkaline phosphatases for the treatment of celiac disease.
Claims27
A method of treating or preventing celiac disease in a patient in need thereof, comprising administering to the patient a composition comprising an alkaline phosphatase (AP)-based agent, optionally intestinal alkaline phosphatase (IAP).
The method of any one of the above claims, wherein the patient has one or more symptoms selected from abdominal cramping, abdominal pain, bloating, gas, diarrhea, loose stools, nausea, vomiting, indigestion, reflux, constipation, vomiting, headache, and tiredness.
The method of any one of the above claims, wherein the patient has low expression and/or activity of IAP in the patient's mucosa.
The method of any one of the above claims, wherein the patient is characterized as having low expression and/or activity of IAP by assaying a biological sample from the subject.
The method of any one of the above claims, wherein the patient is experiencing one or more Celiac Disease Patient Reported Outcome (CeD PRO) abdominal domain symptoms selected from abdominal pain, abdominal cramping, bloating or gas, and/or one or more CeD PRO GI domain symptoms selected from abdominal cramping, abdominal pain, bloating, gas, diarrhea, loose stools, nausea, indigestion, reflux, constipation, and vomiting, and the patient is experiencing at least one CeD PRO non-GI domain symptom.
The method of any one of the above claims, wherein the patient is experiencing one or more CeD PRO Symptomatic days of at least 2, 3, 4, 5, 6, or 7, wherein a CeD PRO Symptomatic days is a day where the mean of abdominal cramping, abdominal pain, bloating, and gas is scored as ≥2.5 or ≥3 out of a 0 to 10 scale, or a day where the mean of diarrhea and loose stool is scored as ≥2.5 or ≥3 out of a 0 to 10 scale, or a day where nausea is scored as ≥2.5 or ≥3 out of a 0 to 10 scale.
The method of any one of the above claims, wherein the patient scores at least 2, or at least 3, or at least 4, or at least 5, or at least 6 on the CeD Gastrointestinal Symptom Rating Scale (CeD GSRS) at the start of treatment using the 1-7 Likert scale.
The method of any one of the above claims, wherein the patient scores at least 2, or at least 3, or at least 4, or at least 5, or at least 6, or 7 on the Total Gastrointestinal Symptom Rating Scale (GSRS) at the start of treatment using the 1-7 Likert scale.
The method of any one of the above claims, wherein the patient experiences at least about 3, 4, 5, 6, 7, 8, 9, 10, or more bowel movements per day at the start of treatment.
The method of any one of the above claims, wherein the patient experiences at least about 4, at least about 5, at least about 6, at least about 7, or at least about 8, or at least about 9, or at least about 10 diarrhea or loose stools per day on the Bristol Form Scale (BSFS) at the start of treatment.
The method of any one of the above claims, wherein the patient experiences 3 diarrhea or loose stools per day with a score of 5-7 as measured by the Bristol Form Scale (BSFS) at the start of treatment.
The method of any one of the above claims, wherein the composition comprising IAP is administered for at least about 9 weeks, or at least about 10 weeks, or at least about 12 weeks.
The method of any one of the above claims, wherein the composition comprising IAP is administered prior to meals.
The method of any one of the above claims, wherein the IAP is selected from human IAP or calf/bovine IAP.
The method of any one of the above claims, wherein the IAP comprises an amino acid sequence having at least about 60%, or at least about 65%, or at least about 70%, or at least about 75%, or at least about 80%, or at least about 85%, or at least about 90%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99%, or at least about 100% identity with any one of SEQ ID NOs:
- 11, 1-6 or 10.
The method of any one of the above claims, wherein the IAP comprises an amino acid sequence having at least about 60%, or at least about 65%, or at least about 70%, or at least about 75%, or at least about 80%, or at least about 85%, or at least about 90%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99%, or at least about 100% identity with SEQ ID NO:
- 2.
The method of any one of the above claims, wherein the composition comprising IAP is administered orally.
The method of any one of the above claims, wherein the composition comprising IAP is formulated for GI release.
The method of any one of the above claims, wherein the bIAP comprises an amino acid sequence having at least about 60%, or at least about 65%, or at least about 70%, or at least about 75%, or at least about 80%, or at least about 85%, or at least about 90%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99% sequence identity to SEQ ID NO:
- 11.
A method of treating celiac disease in a patient in need thereof, comprising administering to the patient a composition comprising an bIAP comprising an amino acid sequence of SEQ ID NO:
- 11, wherein the IAP is formulated for GI release.
Dependencies are inferred from the claim text.